MONROVIA, Calif., April 07, 2022 –(BUSINESS WIRE)–CytoImmune Therapeutics, a clinical-stage immunotherapy company that is developing a novel class of engineered natural killer (NK) cell-based cancer therapies, today announced that Christina Coughlin, M.D., Ph.D., chief executive officer, will participate in the following April investor conferences:
CytoImmune Therapeutics is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel cancer immunotherapy products designed to utilize the power of the engineered cells to activate the patient’s immune system to eliminate cancer cells. The company is advancing a differentiated pipeline of off-the-shelf NK cell therapies, using proprietary, robust and well characterized NK cell expansion and engineering technologies that are designed to provide effector cell therapy with broad immune stimulation, to enable effective tumor killing in both solid tumors and hematologic malignancies. For more information, please visit Cytoimmune.com.
THRUST Strategic Communications